Wentz Scott M, Kim Nathaniel J, Wang Jenny, Amireskandari Annahita, Siesky Brent, Harris Alon
Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine 1160 W Michigan St, Indianapolis, IN 46202 USA.
F1000Prime Rep. 2014 Nov 4;6:102. doi: 10.12703/P6-102. eCollection 2014.
Open-angle glaucoma is a multifactorial optic neuropathy characterized by progressive loss of retinal ganglion cells and their axons. It is an irreversible disease with no established cure. The only currently approved treatment is aimed at lowering intraocular pressure, the most significant risk factor known to date. However, it is now clear that there are other risk factors involved in glaucoma's pathophysiology. To achieve future improvements in glaucoma management, new approaches to therapies and novel targets must be developed. Such therapies may include new tissue targets for lowering intraocular pressure, molecules influencing ocular hemodynamics, and treatments providing neuroprotection of retinal ganglion cells. Furthermore, novel drug delivery systems are in development that may improve patient compliance, increase bioavailability, and decrease adverse side effects.
开角型青光眼是一种多因素导致的视神经病变，其特征是视网膜神经节细胞及其轴突逐渐丧失。它是一种不可逆的疾病，目前尚无治愈方法。目前唯一获批的治疗方法旨在降低眼压，这是迄今为止已知的最重要风险因素。然而，现在很清楚，青光眼的病理生理学还涉及其他风险因素。为了在未来改善青光眼的治疗，必须开发新的治疗方法和新的靶点。此类治疗方法可能包括降低眼压的新组织靶点、影响眼部血流动力学的分子，以及为视网膜神经节细胞提供神经保护的治疗方法。此外，正在开发新型药物递送系统，可能会提高患者的依从性、增加生物利用度并减少副作用。
